Post-exposure vaccination with IMVAMUNE protects against lethal poxvirus infection
The scientific paper "Survival of lethal poxvirus infection in mice depends on TLR9 and therapeutic vaccination provides protection" shows that a single vaccination of IMVAMUNE® could protect a variety of immune suppressed animals on the same day as a lethal challenge with Ectromelia virus; a natural poxvirus infection of mice that closely models smallpox infection in humans. Some of these mice were so immune suppressed that vaccination with a traditional smallpox vaccine (e.g. Dryvax®) led to the death of the animals prior to any challenge with Ectromelia. Not only was IMVAMUNE® therefore shown to be safer than traditional smallpox vaccines, but a single vaccination with IMVAMUNE® given up to 3 days post the lethal challenge with Ectromelia protected the mice. This is the first therapeutic or post-exposure protection, demonstrated for a smallpox vaccine in a relevant animal model.
These data follow Bavarian Nordic's previous observations that IMVAMUNE® induced a faster protective immune response compared to traditional smallpox vaccines. Moreover, IMVAMUNE® is currently in phase two clinical studies and so far more than 1,600 subjects have been vaccinated. IMVAMUNE® has been shown to be well tolerated even in subjects not considered candidates to receive the current first- and second-generation vaccines (e.g. HIV and Atopic Dermatitis patients).
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.